Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

Disclosed is a solid oral dosage pharmaceutical tablet comprising a first layer including at least one opioid, the first layer disposed between two adjacent controlled release layers, at least one of said adjacent controlled release layers including at least one non-opioid analgesic, wherein: a. the two adjacent controlled release layers cover substantially the entire first layer around a peripheral edge thereof, and/or b. a portion of the two adjacent controlled release layers are joined into a...

Disclosed is the use of an inhibitor of soluble epoxide hydrolase ("sEH") and an enzyme selective inhibitor of cyclo-oxygenase-2 (COX-2) in the preparation of a medicament for reducing pain and/or inflammation, wherein said medicament is formulated for co-administering said inhibitor of sEH and said selective inhibitor of COX-2, wherein said inhibitor of sEH has a primary pharmacophore selected from the group consisting of a urea, a carbamate, and an amide, and wherein said selective inhibitor o...

Composiciones farmacéuticas para el tratamiento y/o prevencion de la osteoartritis en mamíferos particularmente humanos que comprenden bicarbonato de sodio y gluconato de calcio y opcionalmente comprende uno o más componentes adicionales. La invencion además proporciona métodos de tratamiento o prevencion de la osteoartritis por administracion a un mamífero preferiblemente por vía de inyeccion intrarticular de una o más composiciones de la invencion. Reivindicacion 13 La composicion farm...

The present invention relates to novel crystalline forms of valdecoxib to processes for their preparation and to pharmaceutical compositions containing them.

The present invention relates to novel crystalline forms of valdecoxib, to processes for their preparation and to pharmaceutical compositions containing them.

PHARMACEUTICAL COMPOSITIONS ARE PROVIDED COMPRISING PARTICULATE VALDECOXIB IN AN AMOUNT OF ABOUT 1 MG TO ABOUT 100 MG AND ONE OR MORE PHARMACEUTICALLY ACCEPTABLE EXCIPIENTS. THE COMPOSITIONS ARE USEFUL IN TREATMENT OR PROPHYLAXIS OF CYCLOOXYGENASE-2 MEDIATED CONDITIONS AND DISORDERS.FIGURE 1

The present invention relates to novel crystalline forms of valdecoxib to processes for their preparation and to pharmaceutical compositions containing them.

The patent application relates to chemical compounds with a basic structure selected from salicylic acid acetylsalicylic acid APHS (o-acetoxyphenylhept-2-inylsulfid) salen ligands diflunisal salsalate benorylate phenylalkanylcarbon acids (particularly fenoprofen ibuprofen ketoprofen flurbiprofen naproxen tolmetin sulindac indomethacin diclofenac carprofen etodolac ketorolac) oxicam inhibitors (particularly Tenoxicam Prioxicam Meloxicam) anthranilic acids: (particularly mefenamic acid meclofenami...